home / openregs / federal_register

federal_register: 2012-29417

All Federal Register documents (rules, proposed rules, notices, presidential documents) from 1994 to present. Nearly 1M documents with full-text search.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

document_number title type abstract publication_date pub_year pub_month html_url pdf_url agency_names agency_ids excerpts regulation_id_numbers
2012-29417 Opioid Drugs in Maintenance and Detoxification Treatment of Opiate Addiction; Proposed Modification of Dispensing Restrictions for Buprenorphine and Buprenorphine Combination as Used in Approved Opioid Treatment Medications Rule This final rule amends the federal opioid treatment program regulations by modifying the dispensing requirements for buprenorphine and buprenorphine combination products approved by the Food and Drug Administration (FDA) for opioid dependence and used in federally certified and registered opioid treatment programs. In particular, this rule would allow opioid treatment programs more flexibility in dispensing take-home supplies of buprenorphine--removing restrictions on the time a patient needs to be in treatment in order to receive take-home supplies--after the assessment and documentation of a patient's responsibility and stability to receive opioid addiction treatment medication. Opioid treatment programs that use these products in the treatment of opioid dependence will continue to adhere to all other federal treatment standards established for methadone. 2012-12-06 2012 12 https://www.federalregister.gov/documents/2012/12/06/2012-29417/opioid-drugs-in-maintenance-and-detoxification-treatment-of-opiate-addiction-proposed-modification https://www.govinfo.gov/content/pkg/FR-2012-12-06/pdf/2012-29417.pdf Health and Human Services Department 221 This final rule amends the federal opioid treatment program regulations by modifying the dispensing requirements for buprenorphine and buprenorphine combination products approved by the Food and Drug Administration (FDA) for opioid dependence and used...  

Links from other tables

  • 1 row from document_number in federal_register_agencies
  • 1 row from fr_document_number in fr_regs_crossref
Powered by Datasette · Queries took 17.272ms · Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API